SLE-associated transverse myelitis successfully treated with Rituximab (anti-CD20 monoclonal antibody)
Authors:
- 18 October 2005
- journal article
- case report
- Published by Springer Nature in Rheumatology International
- Vol. 26 (8) , 771-772
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximabArthritis & Rheumatism, 2004
- Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies.2004
- Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapyLupus, 2003
- An open study of B lymphocyte depletion in systemic lupus erythematosusArthritis & Rheumatism, 2002
- Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus.2002
- Anti‐CD20 monoclonal antibody (Rituximab) for life‐threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosusBritish Journal of Haematology, 2002
- Systemic Lupus Erythematosus Related Transverse Myelitis Presenting Longitudinal Involvement of the Spinal Cord.Internal Medicine, 2002
- Longitudinal myelitis associated with systemic lupus erythematosus: clinical features and magnetic resonance imaging of six casesLupus, 2001
- Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literatureAnnals of the Rheumatic Diseases, 2000